PDSB - PDS Biotech posts Phase 1/2 data for prostate cancer therapy
2023-10-11 08:56:30 ET
More on PDS Biotechnology
- PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript
- PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
- The Prognosis For PDS Biotechnology
- PDS Biotech updates Phase 2 data for lead asset in head and neck cancer
- PDS Biotech gains after updates on pivotal trial for lead asset
For further details see:
PDS Biotech posts Phase 1/2 data for prostate cancer therapy